Compare ARK Genomic Revolution ETF (ARKG) vs Omnicom Group Inc. (OMC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Omnicom Group Inc. — how do they compare? ARK Genomic Revolution ETF trades at $41.25, while Omnicom Group Inc. trades at $82 (market cap $23.35B). The key difference: Omnicom Group Inc. pays a 3.91% dividend while ARK Genomic Revolution ETF pays none. Which is the better fit depends on your goals.
| ARKG | OMC | |
|---|---|---|
Sector | Sector/Thematic | Media |
52-Week High | $43.57 | $85.80 |
52-Week Low | $23.09 | $67.27 |
Market Cap | — | $23.35B |
Enterprise Value | — | $30.58B |
Dividend Yield | — | 3.91% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
Omnicom Group (OMC) trades at $81.93, up 1.36% on the day, with a bullish technical outlook driven by moving averages and a consensus analyst price target of $105.75. The company reported revenue of $17.27 billion in 2025, though net income was negative $54.5 million, reflecting margin pressure. Recent news highlights major client wins, including IBM and Netflix partnerships, and strong free cash flow generation of $2.94 billion from operations.
OMC presents a value opportunity with a low P/E of 12.16 and positive earnings beats in recent quarters, but faces risks from intense competition and fluctuating profitability. The stock's upside potential is supported by analyst optimism and strategic expansions in AI and streaming advertising, though investors should monitor margin recovery and debt levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Omnicom Group Inc.
Omnicom is the world's second- largest ad holding company, based on annual revenue. The firm's services, which include traditional and digital advertising and public relations, are provided worldwide, with over 85% of its revenue coming from more developed regions such as North America and Europe.
Read more on OMC →
